Auto-generated from public data. Not the firm's stated position.
Linc AB appears to focus on early-stage healthcare and life sciences investments, particularly in pharmaceutical development, medical devices, and specialized medical technologies, with typical check sizes in the €1.5M to €3.0M range at pre-seed and seed stages.
Generated 2 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Oct 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.